Discontinued — last reported Q4 '24
Humulin® — Revenue
Eli Lilly Humulin® — Revenue increased by 35.3% to $280.20M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 49.0%, from $188.10M to $280.20M. Over 3 years (FY 2021 to FY 2024), Humulin® — Revenue shows a downward trend with a -9.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests sustained demand or successful market retention for legacy insulin products, while a decrease indicates potential market share erosion due to the adoption of newer diabetes therapies or increased generic competition.
Detailed definition
This metric represents the total gross sales generated from the Humulin product line, which consists of human insulin pr...
Peer comparison
Comparable to legacy product revenue streams or mature pharmaceutical portfolios at peer companies like Novo Nordisk or Sanofi, where established insulin products face similar lifecycle management pressures.
lly_segment_humulin_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $315.30M | $286.70M | $298.80M | $273.20M | $274.00M | $238.20M | $234.00M | $252.00M | $205.30M | $206.70M | $188.10M | $206.20M | $223.60M | $207.10M | $280.20M |
| QoQ Change | — | -9.1% | +4.2% | -8.6% | +0.3% | -13.1% | -1.8% | +7.7% | -18.5% | +0.7% | -9.0% | +9.6% | +8.4% | -7.4% | +35.3% |
| YoY Change | — | — | — | — | -13.1% | -16.9% | -21.7% | -7.8% | -25.1% | -13.2% | -19.6% | -18.2% | +8.9% | +0.2% | +49.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's humulin® — revenue?
- Eli Lilly (LLY) reported humulin® — revenue of $280.20M in Q4 2024.
- How has Eli Lilly's humulin® — revenue changed year-over-year?
- Eli Lilly's humulin® — revenue increased by 49.0% year-over-year, from $188.10M to $280.20M.
- What is the long-term trend for Eli Lilly's humulin® — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's humulin® — revenue has grown at a -9.1% compound annual growth rate (CAGR), from $1.22B to $917.10M.
- What does humulin® — revenue mean?
- The total revenue generated from the sale of Humulin insulin products.